
Part of Bayer’s Roundup Settlement Questioned
Bayer’s relief over its recent deal to settle three-quarters of its outstanding Roundup-related US lawsuits for more than $10 billion altogether could be short-lived.
Bayer’s relief over its recent deal to settle three-quarters of its outstanding Roundup-related US lawsuits for more than $10 billion altogether could be short-lived.
After nearly a year of deliberation, Bayer has clinched a deal to settle three-quarters of its outstanding lawsuits from US plaintiffs who claim that Monsanto’s top-selling herbicide Roundup with the active ingredient glyphosate caused their non-Hodgkins lymphoma (NHL).
Bayer has halted work on a $1 billion production facility for the herbicide active ingredient dicamba in the US state of Louisana but said the decision was not related to a court order mandating that the Environmental Protection Agency (EPA) vacate its approval of the crop protectant active ingredient.
German specialty chemicals producer Lanxess completed the sale of its 40% stake in chemical park operator Currenta to Australia’s Macquarie Infrastructure and Real Assets (MIRA) at the end of April. The sale agreement was concluded in August 2019.
Bayer has set aside €480 million to defend lawsuits brought by people who claim that Monsanto’s glyphosate-based herbicide Roundup caused their non-Hodgkins lymphoma, CEO Werner Baumann said at the company’s annual general meeting on Apr. 28.
The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.